Suppliers and packagers for generic pharmaceutical drug: AVIBACTAM SODIUM; AZTREONAM

AVIBACTAM SODIUM; AZTREONAM

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906	NDA	AbbVie Inc.	0074-3878-10	10 VIAL, SINGLE-DOSE in 1 CARTON (0074-3878-10) / 12 mL in 1 VIAL, SINGLE-DOSE (0074-3878-01)	2025-02-07

AVIBACTAM SODIUM AND AZTREONAM SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

Avibactam sodium, a beta-lactamase inhibitor, and aztreonam, a synthetic monobactam antibiotic, are frequently combined to treat serious Gram-negative bacterial infections, particularly those caused by multidrug-resistant organisms. The reliable supply of both active pharmaceutical ingredients (APIs) and their intermediates is critical for patient access to this combination therapy. This analysis identifies key global suppliers, assesses supply chain vulnerabilities, and outlines regulatory considerations impacting availability.

WHO ARE THE PRIMARY SUPPLIERS OF AVIBACTAM SODIUM AND AZTREONAM?

The global supply chain for avibactam sodium and aztreonam is concentrated among a limited number of API manufacturers, primarily located in Asia.

Avibactam Sodium Suppliers

Major manufacturers of avibactam sodium are concentrated in China and India. These companies specialize in complex organic synthesis and hold significant manufacturing capacity.

• China:
  • Hubei Biocause Pharmaceutical Co., Ltd.: A significant producer of avibactam sodium API. The company has demonstrated consistent production volumes and a global distribution network.
  • Yangzhou Pharmaceutical Co., Ltd.: Another key Chinese supplier with established manufacturing facilities for avibactam sodium.
• India:
  • Divi's Laboratories Limited: A prominent pharmaceutical ingredient manufacturer with a substantial presence in the production of advanced intermediates and APIs, including avibactam sodium.
  • Laurus Labs Limited: While more known for other APIs, Laurus Labs has been involved in the synthesis of complex molecules that could extend to avibactam sodium intermediates.

Aztreonam Suppliers

Aztreonam API manufacturing is also largely dominated by Asian producers, with a notable presence of Chinese and Indian companies.

• China:
  • Nanjing Pharmaceutical Factory Co., Ltd.: A historical producer of aztreonam, maintaining significant market share.
  • Shandong Xinhua Pharmaceutical Co., Ltd.: A diversified pharmaceutical manufacturer with aztreonam listed as a key product.
• India:
  • Sun Pharmaceutical Industries Ltd.: A large Indian pharmaceutical company with diverse API manufacturing capabilities, including aztreonam.
  • Zydus Lifesciences Limited (formerly Cadila Healthcare): Another major Indian player with integrated manufacturing facilities for various antibiotics.

Key Intermediate Suppliers

The synthesis of both avibactam sodium and aztreonam involves several complex chemical intermediates. Disruptions in the supply of these precursors can directly impact the availability of the final APIs.

• Key Intermediates for Avibactam Sodium: These include precursors like pyrazinyl-2-carboxylic acid derivatives and specific amino acid building blocks. Suppliers for these are often specialized chemical manufacturers in China and India.
• Key Intermediates for Aztreonam: Critical intermediates include 2-aminothiazolyl acetic acid derivatives and sulfonation reagents. Manufacturers of these intermediates are found globally, but a significant portion of bulk production is in Asia.

Table 1: Key API and Intermediate Supplier Regions

API/Intermediate Type	Primary Regions of Supply
Avibactam Sodium	China, India
Aztreonam	China, India
Avibactam Intermediates	China, India
Aztreonam Intermediates	China, India, Europe

WHAT ARE THE REGULATORY CONSIDERATIONS FOR AVIBACTAM SODIUM AND AZTREONAM PRODUCTION?

The production and sale of APIs like avibactam sodium and aztreonam are subject to stringent regulatory oversight by health authorities worldwide, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national regulatory bodies.

Good Manufacturing Practices (GMP) Compliance

All manufacturing facilities producing avibactam sodium and aztreonam must adhere to current Good Manufacturing Practices (cGMP) as defined by regulatory agencies. This includes:

• Facility Standards: Ensuring clean, controlled manufacturing environments to prevent contamination.
• Process Validation: Demonstrating that manufacturing processes consistently produce API meeting predefined specifications.
• Quality Control: Implementing rigorous testing for identity, purity, strength, and quality at various stages of production and for the final product.
• Documentation: Maintaining comprehensive records of all manufacturing activities, quality control tests, and deviations.

The FDA conducts regular inspections of API manufacturing sites worldwide, including those in China and India. Failure to meet GMP standards can lead to import alerts, warning letters, and product recalls, directly impacting supply availability.

Drug Master Files (DMFs) and Certificates of Suitability (CEPs)

Manufacturers typically file Drug Master Files (DMFs) with regulatory agencies like the FDA. A DMF provides confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs.

In Europe, manufacturers can obtain a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). A CEP demonstrates that the quality of a substance is suitably controlled by the relevant monograph(s) of the European Pharmacopoeia. Holding a DMF or CEP is often a prerequisite for pharmaceutical companies to use an API from a particular supplier in their finished drug products.

The availability and acceptance of these regulatory filings are critical for market access and supply chain continuity. Companies relying on these APIs must verify the regulatory status of their chosen suppliers.

Impurity Profiles and Control

Regulatory agencies place significant emphasis on controlling impurities in APIs. Specific impurities, such as genotoxic impurities, must be monitored and controlled to very low levels.

• Avibactam Sodium: The synthesis of avibactam sodium can potentially generate specific process-related impurities. Manufacturers must demonstrate robust control strategies for these.
• Aztreonam: Aztreonam synthesis also involves potential impurities arising from side reactions or starting materials.

Manufacturers must provide comprehensive data on impurity identification, qualification, and control strategies in their regulatory submissions. Changes in synthetic routes or process improvements can necessitate re-validation and submission of updated regulatory documentation.

REACH and Environmental Regulations

For APIs manufactured or imported into the European Union, compliance with Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulations may be required for certain chemical intermediates, depending on tonnage and hazard classification. These regulations add a layer of compliance and cost that can influence sourcing decisions.

WHAT ARE THE GEOPOLITICAL AND ECONOMIC FACTORS IMPACTING THE SUPPLY CHAIN?

The pharmaceutical API supply chain, particularly for antibiotics, is subject to various external pressures that can create volatility and risk.

Supply Chain Concentration and Diversification

The heavy reliance on a few countries, primarily China and India, for API manufacturing creates a significant concentration risk.

• Single-Source Dependence: If a major supplier in one of these countries faces production issues due to natural disasters, labor strikes, regulatory actions, or geopolitical tensions, it can lead to widespread shortages of essential medicines.
• Diversification Strategies: Pharmaceutical companies are increasingly seeking to diversify their supplier base to mitigate these risks. This involves identifying and qualifying secondary suppliers, often in different geographical regions, which adds complexity and cost to the supply chain.

Trade Policies and Tariffs

Changes in international trade policies, including the imposition of tariffs on imported chemicals or APIs, can directly impact the cost of avibactam sodium and aztreonam. These costs are often passed down to the finished drug product manufacturers and, ultimately, to healthcare systems and patients. For example, trade disputes between major economies can disrupt established supply routes.

Raw Material Availability and Price Volatility

The cost and availability of raw materials, including solvents, reagents, and basic chemical building blocks, are subject to global market fluctuations. Geopolitical events, energy prices, and increased demand for certain chemicals can lead to price increases and supply constraints for the intermediates required for avibactam sodium and aztreonam synthesis.

Intellectual Property and Patent Landscape

While avibactam and aztreonam themselves are established molecules with expired or expiring patents in many regions, the manufacturing processes and specific polymorphic forms can be subject to ongoing intellectual property protection. Manufacturers must navigate this landscape to ensure freedom to operate and avoid patent infringement. This is particularly relevant for generic API producers.

WHAT ARE THE KEY CHALLENGES AND RISKS IN THE CURRENT SUPPLY CHAIN?

The current supply chain for avibactam sodium and aztreonam faces several persistent challenges and risks that demand strategic management.

Quality Control and Assurance

Maintaining consistent quality across multiple manufacturing sites and geographies is a perpetual challenge.

• Variability in Manufacturing Standards: While GMP is a global standard, the rigor of implementation and enforcement can vary. Pharmaceutical companies must conduct thorough due diligence on their suppliers' quality management systems.
• Auditing and Verification: Regular audits of supplier facilities are essential, but logistical challenges and costs associated with global audits can be significant.

Lead Times and Inventory Management

The complex, multi-step synthesis of these APIs, coupled with global shipping logistics, results in long lead times from order placement to delivery.

• Extended Lead Times: Lead times for avibactam sodium and aztreonam can range from several months to over a year, depending on the supplier and current demand.
• Inventory Optimization: Balancing the need for sufficient inventory to ensure uninterrupted supply against the costs of holding large stockpiles of expensive APIs is a critical strategic decision for drug manufacturers.

Environmental, Social, and Governance (ESG) Factors

Increasingly, stakeholders are scrutinizing the ESG performance of pharmaceutical supply chains.

• Environmental Impact: API manufacturing can be resource-intensive and generate waste. Suppliers with strong environmental management systems and demonstrable efforts to reduce their carbon footprint and waste generation are becoming more attractive.
• Labor Practices: Ensuring fair labor practices and safe working conditions at manufacturing facilities is a growing concern for multinational pharmaceutical companies.

Antimicrobial Resistance (AMR) and Demand Fluctuations

While the combination of avibactam sodium and aztreonam addresses serious AMR threats, the demand for these drugs can fluctuate based on the prevalence of specific resistant pathogens and prescribing patterns.

• Forecasting Accuracy: Accurately forecasting demand for such specialized antibiotics is challenging, making it difficult for API manufacturers to precisely align production levels.
• "Bullwhip Effect": Inaccurate demand forecasts can lead to overstocking or understocking throughout the supply chain, amplifying volatility.

WHAT ARE THE STRATEGIES TO MITIGATE SUPPLY CHAIN RISKS?

To ensure a robust and reliable supply of avibactam sodium and aztreonam, pharmaceutical companies and healthcare providers can implement several mitigation strategies.

Dual Sourcing and Supplier Diversification

Establishing relationships with multiple qualified suppliers in different geographic regions is the most effective strategy for mitigating single-source risk. This requires significant investment in supplier qualification, audits, and inventory management.

Strategic Inventory Management

Holding strategic buffer stocks of critical APIs and intermediates at various points in the supply chain can provide a cushion against short-term disruptions. This requires sophisticated inventory forecasting and management systems.

Backward Integration and In-House Manufacturing

For highly critical APIs, some pharmaceutical companies may consider backward integration, producing key intermediates or even the API in-house. This offers greater control but involves substantial capital investment and specialized expertise.

Collaboration with Regulatory Authorities and Industry Consortia

Proactive engagement with regulatory agencies to understand evolving requirements and participate in industry initiatives aimed at improving supply chain resilience can be beneficial.

Supply Chain Visibility and Technology Adoption

Implementing advanced supply chain visibility tools, including track-and-trace technologies and data analytics platforms, can provide real-time insights into inventory levels, shipment status, and potential disruptions.

Key Takeaways

• The global supply of avibactam sodium and aztreonam APIs is concentrated among a limited number of manufacturers, primarily in China and India.
• Regulatory compliance, including cGMP adherence and successful DMF/CEP filings, is paramount for API suppliers and directly impacts market access and availability.
• Geopolitical factors, trade policies, and raw material price volatility pose significant risks to supply chain stability and cost.
• Challenges such as quality control variability, long lead times, and fluctuating demand necessitate robust risk mitigation strategies.
• Dual sourcing, strategic inventory management, and enhanced supply chain visibility are critical for ensuring a reliable supply of these essential antibiotics.

Frequently Asked Questions

1. What is the primary manufacturing region for avibactam sodium and aztreonam APIs? The primary manufacturing regions are China and India, with a significant concentration of both API and intermediate production in these countries.

2. How do regulatory bodies like the FDA and EMA ensure the quality of imported APIs such as avibactam sodium and aztreonam? Regulatory bodies ensure quality through facility inspections to verify cGMP compliance, review of Drug Master Files (DMFs) or Certificates of Suitability (CEPs), and rigorous testing of imported drug products.

3. What are the potential impacts of trade tariffs on the cost of avibactam sodium and aztreonam? Trade tariffs can increase the cost of imported APIs and their raw materials, leading to higher prices for finished drug products and potentially impacting patient access.

4. What steps can a pharmaceutical company take if a primary supplier of avibactam sodium experiences a production shutdown? A company can mitigate this by having pre-qualified secondary suppliers, holding strategic inventory buffers, and rapidly activating contingency plans.

5. How does the issue of antimicrobial resistance (AMR) affect the supply chain planning for avibactam sodium and aztreonam? AMR drives demand for these combination therapies, making accurate demand forecasting crucial for API manufacturers to align production and avoid shortages, but forecasting remains a significant challenge.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website on DMFs] (Note: Actual URL would be required if available) [2] European Medicines Agency. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from [EMA Website on CEPs] (Note: Actual URL would be required if available) [3] European Chemicals Agency. (n.d.). REACH. Retrieved from [ECHA Website on REACH] (Note: Actual URL would be required if available) [4] World Health Organization. (2020). Antimicrobial resistance: global report on surveillance. Geneva: World Health Organization. (Note: Specific publication details would be required if available)